All Type of News
New insights into Brilinta
The efficacy of AstraZeneca’s Brilinta (ticagrelor), a platelet aggregation inhibitor, has been re-evaluated in advanced countries including the United States, United Kingdom and Germany.
In a study of 44 American ...
Guerbet releases new contrast media for medical imaging
Guerbet Korea, the contrast agent specialist for medical imaging, said recently that a new pharmaceutical filling and packaging unit ScanBag will be available at Asan Medical Center from next month.
The ScanBag, wh...
Kwangdong to re-launch Prospan cough syrup
Kwangdong Pharmaceutical said yesterday that it will re-distribute Prospan cough syrup in Korea from August under an exclusive marketing and distribution partnership with Germany based Engelhard.
Prospan cough syru...
Pradaxa to be covered by health insurance
Pradaxa (dabigatran etexilate), the blood thinning drug by the German pharmaceutical Company Boehringer Ingleheim, has moved closer to get listed in the national health insurance, with the Health Insurance Review and ...
Drug makers perform worst in first half
Local pharmaceutical companies saw a substantial setback in their performance in their fiscal first half with profits more than halved after a government-mandated price cut came into effect in April, Yakup.com, a phar...
Cosmetics and quasi-drug makers oblige to describe retail prices
The government has revised laws to describe the pricing of cosmetics and quasi-drugs on their packages, when their initial prices are re-adjusted during bargain sales, officials said last Thursday.
Complaints over ...
Dong-A Q2 sales rise 9.8%
Dong-A Pharmaceutical, the country’s top drug maker, said Friday its sales climbed 9.8 percent on-year to 246.5 billion won in the second quarter, fueled by booming demand for over-the-counter (OTC) drugs and overseas...
Omacor patents are valid until 2020, Kuhnil says
Kuhnil Pharmaceutical has recently confirmed that the Korean patents for Omacor (omega-3-acid ethyl esters), which has been also sold under the brand name of Lovaza in the U.S., are valid until February 2020 as an U.S...
National Assembly to back local pharmaceutical industry
The National Assembly has unveiled an ambitious vision to support the domestic pharmaceutical industry through further expansion of R&D budget alloted to the Ministry of Health and Welfare and offering various tax ben...
Korea to develop 30 new drugs by 2020
Korea’s 43 innovative pharmaceutical firms are expected to develop 30 new products by 2020, it was learned Thursday from a local conference ‘Pharma Korea 2020.’
According to a conference organizer, the companies wi...
